{"id":"NCT00501969","sponsor":"UCB Pharma","briefTitle":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease","officialTitle":"An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2007-07-17","resultsPosted":"2010-01-12","lastUpdate":"2014-10-02"},"enrollment":395,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Stage Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["NeuproÂ®"]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"}],"summary":"The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","timeFrame":"five years","effectByArm":[{"arm":"Rotigotine","deltaMin":357,"sd":null}],"pValues":[]},"eligibility":{"minAge":"31 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":53,"countries":["Australia","Austria","Croatia","Czechia","Finland","France","Germany","Hungary","Israel","Italy","New Zealand","Norway","Poland","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":148,"n":395},"commonTop":["Somnolence","Fall","Dyskinesia","Nausea","Back pain"]}}